BioCentury | May 14, 2020
Deals

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

...Xetra:BAYN) for $240 million up front. In 2018, Versant’s Inception 4 start-up was acquired by Ophthotech Corp....
BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

...to treat Leber congenital amaurosis type 10 (LCA10) due to mutations in CEP290. Iveric (formerly Ophthotech Corp....
BioCentury | Apr 19, 2019
Company News

Ophthotech rebrands as Iveric as focus turns to retinal gene therapies

Ophthotech Corp. (NASDAQ:OPHT) changed its name and ticker to Iveric bio Inc. (NASDAQ:ISEE) as part of its shift to focus on gene therapies to treat orphan inherited retinal diseases. Last week, the company exercised its...
BioCentury | Dec 6, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

...HtrA serine peptidase 1 (HTRA1) Preclinical studies suggest HTRA1 inhibitors could help treat dry AMD Ophthotech Corp....
BioCentury | Nov 14, 2018
Translation in Brief

Gene therapy rising

...from animal proof-of-concept to IND-enabling studies. By licensing gene therapy programs at the preclinical stage, Ophthotech...
...others could help overcome the manufacturing bottleneck (see “Academia’s Manufacturing Problem” ). Through its partnerships, Ophthotech...
...apparent that gene therapy was going to play a major role in ophthalmology.” Glenn Sblendorio, Ophthotech...
BioCentury | Nov 2, 2018
Finance

Bye-bye, build-to-buy

...to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech Corp....
...serine peptidase 1 (HTRA1) to treat age-related retinal diseases, including dry age-related macular degeneration (AMD). Ophthotech...
...IND for its lead HTRA1 inhibitor in late 2020. Versant gained a 12.5% stake in Ophthotech...
BioCentury | Jun 8, 2018
Company News

Opthotech gains gene therapy for ophran vision-loss disease

...AAV is designed to knock down mutant RHO expression and deliver a functional replacement gene. Ophthotech...
...universities will also be eligible for royalties in the low single-digit percentages of net sales. Ophthotech...
...Ophthotech has an option to exclusive rights to patents or patent applications from the research. Ophthotech...
BioCentury | Jun 7, 2018
Company News

Ophthotech gains gene therapy for orphan vision-loss disease

...AAV is designed to knock down mutant RHO expression and deliver a functional replacement gene. Ophthotech...
...universities will also be eligible for royalties in the low single-digit percentages of net sales. Ophthotech...
...Ophthotech has an option to exclusive rights to patents or patent applications from the research. Ophthotech...
BioCentury | May 11, 2018
Finance

Amplifying oligos

...the low deal pace for aptamers is largely due to two high-profile clinical disappointments -- Ophthotech Corp.’s...
...Therapeutics Inc., Cambridge, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Noxxon Pharma N.V., Berlin, Germany Ophthotech Corp....
BioCentury | Feb 23, 2018
Clinical News

Apellis reports 18-month Phase II data for GA candidate

...BioCentury, Oct. 13, 2017 ). Zimura avacincaptad pegol, a synthetic aptamer that inhibits C5 from Ophthotech Corp....
Items per page:
1 - 10 of 121
BioCentury | May 14, 2020
Deals

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

...Xetra:BAYN) for $240 million up front. In 2018, Versant’s Inception 4 start-up was acquired by Ophthotech Corp....
BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

...to treat Leber congenital amaurosis type 10 (LCA10) due to mutations in CEP290. Iveric (formerly Ophthotech Corp....
BioCentury | Apr 19, 2019
Company News

Ophthotech rebrands as Iveric as focus turns to retinal gene therapies

Ophthotech Corp. (NASDAQ:OPHT) changed its name and ticker to Iveric bio Inc. (NASDAQ:ISEE) as part of its shift to focus on gene therapies to treat orphan inherited retinal diseases. Last week, the company exercised its...
BioCentury | Dec 6, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

...HtrA serine peptidase 1 (HTRA1) Preclinical studies suggest HTRA1 inhibitors could help treat dry AMD Ophthotech Corp....
BioCentury | Nov 14, 2018
Translation in Brief

Gene therapy rising

...from animal proof-of-concept to IND-enabling studies. By licensing gene therapy programs at the preclinical stage, Ophthotech...
...others could help overcome the manufacturing bottleneck (see “Academia’s Manufacturing Problem” ). Through its partnerships, Ophthotech...
...apparent that gene therapy was going to play a major role in ophthalmology.” Glenn Sblendorio, Ophthotech...
BioCentury | Nov 2, 2018
Finance

Bye-bye, build-to-buy

...to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech Corp....
...serine peptidase 1 (HTRA1) to treat age-related retinal diseases, including dry age-related macular degeneration (AMD). Ophthotech...
...IND for its lead HTRA1 inhibitor in late 2020. Versant gained a 12.5% stake in Ophthotech...
BioCentury | Jun 8, 2018
Company News

Opthotech gains gene therapy for ophran vision-loss disease

...AAV is designed to knock down mutant RHO expression and deliver a functional replacement gene. Ophthotech...
...universities will also be eligible for royalties in the low single-digit percentages of net sales. Ophthotech...
...Ophthotech has an option to exclusive rights to patents or patent applications from the research. Ophthotech...
BioCentury | Jun 7, 2018
Company News

Ophthotech gains gene therapy for orphan vision-loss disease

...AAV is designed to knock down mutant RHO expression and deliver a functional replacement gene. Ophthotech...
...universities will also be eligible for royalties in the low single-digit percentages of net sales. Ophthotech...
...Ophthotech has an option to exclusive rights to patents or patent applications from the research. Ophthotech...
BioCentury | May 11, 2018
Finance

Amplifying oligos

...the low deal pace for aptamers is largely due to two high-profile clinical disappointments -- Ophthotech Corp.’s...
...Therapeutics Inc., Cambridge, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Noxxon Pharma N.V., Berlin, Germany Ophthotech Corp....
BioCentury | Feb 23, 2018
Clinical News

Apellis reports 18-month Phase II data for GA candidate

...BioCentury, Oct. 13, 2017 ). Zimura avacincaptad pegol, a synthetic aptamer that inhibits C5 from Ophthotech Corp....
Items per page:
1 - 10 of 121